Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hematological Malignancies
100%
Malignancy
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Myeloablative Conditioning
100%
Blastic Phase
100%
Transplantation
75%
Donor Lymphocyte Infusion
75%
Donor chimerism
75%
Secondary AML
50%
Primary Refractory
50%
Chronic Graft-versus-host Disease (cGVHD)
50%
Graft-versus-host Disease (GvHD)
25%
Nonmyeloablative
25%
Mycophenolate Mofetil
25%
Clinical High Risk
25%
Engraftment
25%
Fludarabine
25%
Ara-C
25%
Drug Therapy
25%
Relapsed ALL
25%
Refractory AML
25%
Chronic Phase
25%
GVHD Prophylaxis
25%
Standard Risk
25%
HLA-matched Donor
25%
Post-transplant Lymphoproliferative Disorder
25%
Cytoreductive Surgery
25%
Pretransplant
25%
Minimal Residual Disease
25%
Conditioning Regimen
25%
Immunotherapy Efficacy
25%
Aggressiveness
25%
Antithymocyte Globulin
25%
Intracranial Hemorrhage
25%
Accelerated Phase
25%
Chimerism
25%
Early Death
25%
Conventional Dose
25%
Blastic
25%
Relapsed Disease
25%
Platelet Transfusion
25%
Reduced Toxicity
25%
Filgrastim
25%
Second Remission
25%
Severe Toxicity
25%
Melphalan
25%
Stem Cell Donor
25%
Patient Cells
25%
Peripheral Blood Hematopoietic Stem Cells
25%
Host Tolerance
25%
Molecular Remission
25%
As(III)
25%
Secondary Progressive
25%
Non-myeloablative Transplantation
25%
Transplant Recipients
25%
Medicine and Dentistry
Hematopoietic Cell
100%
Cell Transplantation
100%
Hematologic Malignancy
100%
Chronic Myelogenous Leukemia
100%
Myeloablative Conditioning
100%
Cancer
66%
Acute Myelogenous Leukemia
50%
Donor Lymphocyte Infusion
50%
Diseases
50%
Secondary Acute Myeloid Leukemia
33%
Acute Lymphocytic Leukemia
33%
Cytarabine
16%
Cerebral Hemorrhage
16%
Drug Therapy
16%
Engraftment
16%
Fludarabine
16%
Acute Graft Versus Host Disease
16%
Chronic Graft Versus Host Disease
16%
Stem Cell
16%
T Lymphocyte
16%
Posttransplant Lymphoproliferative Disease
16%
Mycophenolate Mofetil
16%
Minimal Residual Disease
16%
Nonmyeloablative Conditioning
16%
Thrombocyte Transfusion
16%
Melphalan
16%
Globulin
16%
Immunosuppressive Drug
16%
Filgrastim
16%
Median Follow Up
16%
Pharmacology, Toxicology and Pharmaceutical Science
Hematologic Malignancy
100%
Diseases
100%
Remission
66%
Secondary Acute Myeloid Leukemia
66%
Pharmacotherapy
33%
Acute Graft Versus Host Disease
33%
Mycophenolate Mofetil
33%
Brain Hemorrhage
33%
Chronic Graft Versus Host Disease
33%
Immunosuppressive Agent
33%
Melphalan
33%
Cytarabine
33%
Posttransplant Lymphoproliferative Disease
33%
Filgrastim
33%
Fludarabine
33%
Minimal Residual Disease
33%
Globulin
33%
Immunology and Microbiology
Cell Transplantation
100%
Hematopoietic Cell
100%
Lymphocyte
60%
Engraftment
20%
Platelet
20%
Immunosuppressive Drug
20%
Stem Cell
20%
Acute Graft Versus Host Disease
20%
Chronic Graft Versus Host Disease
20%
Filgrastim
20%
T Cell
20%
Mycophenolate Mofetil
20%
Drug Therapy
20%
Globulin
20%